NeuroMetrix, Inc.
62 Fourth Avenue
Waltham
Massachusetts
02451
United States
Tel: 781-890-9989
Fax: 781-890-1556
Website: http://www.neurometrix.com/
Email: info@neurometrix.com
432 articles about NeuroMetrix, Inc.
-
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
3/14/2024
NeuroMetrix, Inc. noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy.
-
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
3/13/2024
NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022.
-
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
2/22/2024
NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.
-
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
2/15/2024
NeuroMetrix, Inc. announced that it plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024.
-
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
2/13/2024
NeuroMetrix, Inc. announced a process to review strategic options to promote growth of its Quell® neuromodulation and DPNCheck® neurodiagnostic businesses and to maximize shareholder value.
-
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
1/8/2024
NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on January 10, 2024.
-
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
12/12/2023
NeuroMetrix, Inc. (Nasdaq: NURO) reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with post-acute COVID-19 syndrome (PACS), commonly called Long COVID.
-
NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)
12/5/2023
NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of results from a NIH-funded clinical trial of Quell titled "Wireless transcutaneous electric nerve stimulation (TENS) for chronic chemotherapy-induced peripheral neuropathy (CIPN): a proof-of-concept randomized clinical trial."
-
NeuroMetrix Announces One-for-Eight Reverse Stock Split
11/20/2023
NeuroMetrix, Inc. announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00 pm on November 21, 2023.
-
NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023
10/30/2023
NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on Wednesday, November 1, 2023.
-
NeuroMetrix Reports Q3 2023 Business Highlights
10/26/2023
NeuroMetrix, Inc. reported business and financial highlights for the quarter and nine month period ended September 30, 2023.
-
NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call
10/23/2023
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q3 2023 business and financial highlights before the opening of the market on October 26, 2023.
-
NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia
10/2/2023
NeuroMetrix, Inc. announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association.
-
NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023
9/28/2023
NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on October 4, 2023.
-
NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023
8/30/2023
NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on September 6, 2023.
-
NeuroMetrix Reports Q2 2023 Business Highlights
7/27/2023
NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and six months period ended June 30, 2023.
-
NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call
7/20/2023
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the market on July 27, 2023.
-
NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia
7/11/2023
NeuroMetrix, Inc. announced expansion of its sales force to drive further adoption of Quell® Fibromyalgia, which is the first and only medical device authorized by the U.S. Food and Drug Administration to help reduce the symptoms of fibromyalgia.
-
Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients
6/28/2023
NeuroMetrix, Inc. noted the recent publication of two large studies that support the clinical utility of DPNCheck screening in people with diabetes.
-
Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study
6/7/2023
NeuroMetrix, Inc. (Nasdaq: NURO) noted presentation of new clinical data at the Diabetes UK meeting held April 23-26 in Liverpool, UK.